Home | Meeting coverage | EULAR 2021

Spotlight Discussion

EULAR 2021

P. Sewerin, F. Behrens, T. Kvien, E. Choy, A. Balsa

Difficult to treat RA - hot topics and challenges

EULAR 2021

P. Sewerin, F. Behrens, T. Kvien, E. Choy, A. Balsa

Early detection and treatment of RA

EULAR 2021

P. Sewerin, F. Behrens, T. Kvien, E. Choy, A. Balsa

RA treatment - status and perspectives

EULAR 2021

F. Behrens, P. Sewerin, A. Askari, V. Goëb, E. Lubrano

Early detection of PsA & patient stratification

EULAR 2021

F. Behrens, P. Sewerin, A. Askari, V. Goëb, E. Lubrano

Update GRAPPA recommendations & axial PsA vs axSpA

EULAR 2021

F. Behrens, P. Sewerin, A. Askari, V. Goëb, E. Lubrano

Treatment decissions and therapeutic options in PsA

Rheumatoid Arthritis – ENG

EULAR 2021

Alejandro Balsa, MD, Phd

Definition of difficult to treat rheumatoid arthritis

EULAR 2021

Ernest Choy, MD

Clinical outcome after switching between IL-6 and JAK...

EULAR 2021

Tore Kvien, MD

Influence of comorbitidy on mortality

EULAR 2021

Vincent Goëb, MD,PhD

JAKi in real life!

EULAR 2021

Alejandro Balsa, MD, PhD

Passive smoking in childhood and adulthood increases...

EULAR 2021

Ayman Askari, MD

Switching of treatment from reference etanercept to...

EULAR 2021

Vincent Goëb, MD, PhD

Recurrence of joint inflammation

EULAR 2021

Tore Kvien, MD

Risk of cardiovascular events and disease activity

EULAR 2021

Ernest Choy, MD

Using anti-TNF to deliver corticosteroids to...

EULAR 2021

Tore Kvien, MD

Interstitial lung disease in patients with RA

EULAR 2021

Vincent Goëb, MD, PhD

RA activity and risk of complications after...

EULAR 2021

Vincent Goëb, MD, PhD

Vitamin D level in response to biologics

Rheumatoid Arthritis – FRA/ESP/NOR

EULAR 2021

Vincent Goëb, MD, PhD

Où les arthrites récidivent-elles?

EULAR 2021

Alejandro Balsa, MD, PhD

El tabaquismo pasivo aumenta el riesgo de padecer una...

EULAR 2021

Tore Kvien, MD

Påvirkning av komorbiditeter på mortalitet

EULAR 2021

Vincent Goëb, MD, PhD

Complications après arthroplastie selon l’activité du...

EULAR 2021

Alejandro Balsa, MD, PhD

Definición de artritis reumatoide difícil de tratar

EULAR 2021

Tore Kvien, MD

Risiko for kardiovaskulære hendelser og...

EULAR 2021

Vincent Goëb, MD, PhD

Vitamine D et réponse aux biomédicaments

EULAR 2021

Tore Kvien, MD

Interstitiell lungesykdom hos pasienter med RA

EULAR 2021

Vincent Goëb, MD, PhD

JAKi dans la vraie vie!

Psoriatic arthritis – ENG

EULAR 2021

Frank Behrens, MD

Secukinumab: Adherence in PsA and AS

EULAR 2021

Philipp Sewerin, MD, PD

Role of Sex and Weight on PsA

EULAR 2021

Philipp Sewerin, MD, PD

GRAPPA Recommendations 2021

EULAR 2021

Frank Behrens, MD

Deucravacitinib (TYK2 Inhibitor) in Psoriasis and...

EULAR 2021

Philipp Sewerin, MD, PD

Power-Doppler ultrasound of the achilles tendon to...

EULAR 2021

Philipp Sewerin, MD, PD

Hyperuricemia: increased risk of severe PsA course

EULAR 2021

Philipp Sewerin, MD, PD

Faeceal microbiota transplantation

EULAR 2021

Frank Behrens, MD

Cardiovascular risk and metabolomic profiling in PsA

Psoriatic arthritis – GER

EULAR 2021

Frank Behrens, MD

Secukinumab: Adhärenz bei PsA and AS

EULAR 2021

Philipp Sewerin, MD, PD

Rolle von Geschlecht und Gewicht

EULAR 2021

Philipp Sewerin, MD, PD

GRAPPA Empfehlungen 2021

EULAR 2021

Frank Behrens, MD

Deucravacitinib (TYK 2 Inhibitor) neu bei PsA und...

EULAR 2021

Philipp Sewerin, MD, PD

Power-Doppler-Sono AS: Differenzierung Belastung vs....

EULAR 2021

Philipp Sewerin, MD, PD

Cave Hyperurikämie: Erhöhtes Risiko für schweren...

EULAR 2021

Frank Behrens, MD

Kardiovaskuläres Risiko und metabolomisches Profil bei...

Axial Spondyloarthritis – ENG

EULAR 2021

Francesco Ciccia, MD, PhD

Impact of sex on BASDAI scores

EULAR 2021

Xabier Michelena Vegas, MD

Do patients with axSpA help us?

EULAR 2021

Ayman Askari, MD

Non-radiographic or radiographic axial SpA - does it...

EULAR 2021

Francesco Ciccia, MD, PhD

Feasibilty of anti-TNF tapering in low disease...

EULAR 2021

Xabier Michelena Vegas, MD

Radiographic progression in axSpA

Axial Spondyloarthritis – ESP

EULAR 2021

Francesco Ciccia, MD, PhD

Impatto del sesso sugli score del BASDAI

EULAR 2021

Xabier Michelena Vegas, MD

¿Nos ayudan los pacientes con espondiloartritis axial?

EULAR 2021

Francesco Ciccia, MD, PhD

fattibilità della riduzione del dosaggio degli anti-TNF...

EULAR 2021

Xabier Michelena Vegas, MD

Progresión radiográfica en espondiloartritis axial

COVID-19 – ENG

EULAR 2021

Ernest Choy, MD

Outcome of Covid-19 in Rheumatoid Arthritis under...

EULAR 2021

Bimba Franziska Hoyer, MD

Risk factors of COVID-19 course in SLE

EULAR 2021

Ayman Askari, MD

COVID-19 outcome in inflammatory arthropathy patients

EULAR 2021

Alejandro Balsa, MD, PhD

Immunogenicity of mRNA-COVID-19 vaccine in patients...

EULAR 2021

Bimba Franziska Hoyer, MD

Influence of TNF-Inhibition on COVID-19

EULAR 2021

Bimba Franziska Hoyer, MD

Rituximab and COVID-19 (Nat. French Registry Study)

EULAR 2021

Bimba Franziska Hoyer, MD

Rituximab and COVID-19 (Multicenter-Study)

EULAR 2021

Bimba Franziska Hoyer, MD

COVID-19 Vaccination in patients with rheumatic disease

COVID-19 – ESP/GER

EULAR 2021

Alejandro Balsa, MD, PhD

Immunogenicidad de la vacuna mRNA-COVID-19 en pacientes...

EULAR

Bimba Franziska Hoyer, MD

SARS-CoV2-Impfung bei Rheumapatienten

EULAR 2021

Bimba Franziska Hoyer, MD

Patientenumfrage während der Pandemie

EULAR 2021

Bimba Franziska Hoyer, MD

COVID-19 bei SLE

EULAR 2021

Bimba Franziska Hoyer, MD

Einfluss von TNF-Blockern auf COVID-19-Verlauf

EULAR 2021

Bimba Franziska Hoyer, MD

Rituximab bei COVID-19 (franz. Registerdaten)

EULAR 2021

Bimba Franziska Hoyer, MD

Rituximab bei COVID-19 (Multicenter-Studien)

Lupus erythematosus – ENG

EULAR 2021

Bimba Franziska Hoyer, MD

New therapy for cutaneous manifestations

EULAR 2021

Bimba Franziska Hoyer, MD

Convincing Anifrolumab data on efficacy and drug...

EULAR 2021

Bimba Franziska Hoyer, MD

Combination of Belimumab and Rituximab is beneficial

Lupus erythematosus – GER

EULAR 2021

Bimba Franziska Hoyer, MD

Neue Therapie für kutane Manifestationen

EULAR 2021

Bimba Franziska Hoyer, MD

Anifrolumab in Wirksamkeit und Verträglichkeit...

EULAR 2021

Bimba Franziska Hoyer, MD

Kombination Belimumab und Retuximab vorteilhaft

Vasculitis – ENG

EULAR 2021

Carlo Salvarani, MD

Efficcacy and Safety of TNF-α Blockers and Tocilizumab...

EULAR 2021

Ayman Askari, MD

What is new in Giant Cell Arteritis?

EULAR 2021

Carlo Salvarani, MD

Tocilizumab Monotherapy for Giant Cell Arteritis - the...

EULAR 2021

Ayman Askari, MD

Ultrasound halo sign as a potential monitoring tool for...

VASCULITIS – ITA

EULAR 2021

Carlo Salvarani, MD

Efficacia e sicurezza degli anti-TNF e del tocilizumab...

EULAR 2021

Carlo Salvarani, MD

Monoterapia con tocilizumab nella arterite a cellule...

Systemic Sclerosis – ENG

EULAR 2021

Ayman Askari, MD

Lung involvement: diagnostic work-up and  new treatment...

Varia – ENG

EULAR 2021

Alejandro Balsa, MD, PhD

Risk factors for ADAb formation: Data from the NOR-DRUM...

EULAR 2021

Tore Kvien, MD

Therapeutic drug monitoring and immunogenicity

EULAR 2021

Ayman Askari, MD

Secukinumab in patients with rotator cuff tendinopathy

EULAR 2021

Ayman Askari, MD

Fatigue in Arthritis, SpA & systemic rheumatic diseases

EULAR 2021

Ayman Askari, MD

Lyme disease: Myths and reality

Varia – POL/ESP/NOR

EULAR 2021

Zuber Zbigniew, MD, PhD

Co nowego w reumatologii dziecięcej

EULAR 2021

Alejandro Balsa, MD, PhD

Factores de riesgo del desarrollo de anticuerpos...

EULAR 2021

Tore Kvien, MD

Therapeutic drug monitoring (TDM) og immunogenisitet

EULAR 2021

Zuber Zbigniew, MD, PhD

EULAR, najnowsze postępy w reumatologii